Compare MYSZ & AEMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYSZ | AEMD |
|---|---|---|
| Founded | 1999 | 1984 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 2.1M |
| IPO Year | 2017 | 2008 |
| Metric | MYSZ | AEMD |
|---|---|---|
| Price | $0.45 | $0.72 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 69.7K | ★ 248.2K |
| Earning Date | 04-15-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.40 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $142,000.00 | N/A |
| Revenue This Year | $41.64 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 125.40 | N/A |
| 52 Week Low | $0.38 | $0.51 |
| 52 Week High | $1.65 | $5.89 |
| Indicator | MYSZ | AEMD |
|---|---|---|
| Relative Strength Index (RSI) | 49.23 | 21.68 |
| Support Level | $0.38 | $0.51 |
| Resistance Level | $0.67 | $0.82 |
| Average True Range (ATR) | 0.05 | 0.17 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 99.90 | 5.10 |
My Size Inc is a fashion technology company operating an integrated portfolio of businesses designed to address the pressing challenges facing fashion brands and retailers today - size and fit accuracy, excess inventory management, circular economy solutions, and international market distribution. The company, through its subsidaries provide end-to-end support across the fashion value chain; delivers AI-driven size and fit solutions for fashion e-commerce companies. The firm has the following four segments: (i) Fashion e-commerce platform, (ii) SaaS solutions, (iii) resale platform for apparel, and (iv) wholesaling of footwear. The company generates the majority of its revenue from the fashion e-commerce platform segment.
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.